Severe haemophilia A patients have reduced numbers of peripheral memory B cells

Haemophilia

Volumn 18, Issue 3, 2012, Pages 437-443

  Irigoyen, M B ^a   Felippo, M E ^a   Primiani, L ^b   Candela, M ^c   Bianco, R P ^b,c   De Bracco, M M ^a   Galassi, N ^a  

^a ACADEMIA NACIONAL DE MEDICINA   (Argentina)

^b Fundación Argentina de la Haemofilia   (Argentina)

^c INST DE INVEST HEMATOLOGICAS   (Argentina)

Author keywords

Anti FVIII antibodies; Haemophilia; Memory B cells

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR; CD27 ANTIGEN; CD70 ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CELL MIGRATION; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FLOW CYTOMETRY; HEMOPHILIA A; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE; MEMORY CELL; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ADOLESCENT; ANTIBODIES; ANTIGENS, CD70; B-LYMPHOCYTES; BLOOD COAGULATION FACTOR INHIBITORS; CHILD; CHILD, PRESCHOOL; FACTOR VIII; FLOW CYTOMETRY; HEMOPHILIA A; HUMANS; IMMUNOLOGIC MEMORY; MALE; PHENOTYPE; YOUNG ADULT;

EID: 84860337631     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02642.x     Document Type: Article

References (25)

1. Reding M. Immunological aspects of inhibitor development. Haemophilia 2006; 12: 30-6.
2. Dazzi F, Tison T, Vianello F et al. High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: a possible role for half-life of transfused FVIII. Br J Haematol 1996; 93: 688-93.
3. Astermark J. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia. Haemophilia 2006; 12(Suppl. 3): 52-60.
4. Coppola A, Di Minno M, Santagostino E. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Br J Haematol 2010; 150: 515-28.
5. Waters B, Lillicrap D. The molecular mechanisms of immunomodulation and tolerance induction to factor VIII. J Thromb Haemost 2009; 7: 1446-56.
6. Hausi C, Ahmad R, Sasgary M et al. High-dose factor VIII inhibits factor VIII specific memory B cells in hemophilia A with factor VIII inhibitors. Blood 2005; 106: 3415-22.
7. Sanz I, Wei C, Eun-Hyung Lee F, Anolik J. Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol 2008; 20: 67-82.
8. Klein U, Rajewsky K, Küppers R. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med 1998; 188: 1679-89.
9. H genes with low frequency of somatic mutation. J Immunol 2006; 177: 3728-36.
10. Agematsu K, Nagumo H, Yang F et al. B cell subpopulations separated by CD27 and crucial collaboration of CD27+ B cells and helper T cells in immunoglobulin production. Eur J Immunol 1997; 27: 2073-9.
11. Muehlinghaus G, Cigliano L, Huehn S et al. Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. Blood 2005; 105: 3965-71.
12. Glouchkova L, Ackermann B, Zibert A et al. The CD70/CD27 pathway is critical for stimulation of an effective cytotoxic T cell response against B cell precursor acute lymphoblastic leukemia. J Immunol 2009; 182: 718-25.
13. Groth C, Dräger R, Warnatz K et al. Impaired up-regulation of CD70 and CD86 in naive (CD27-) B cells from patients with common variable immunodeficiency (CVID). Clin Exp Immunol 2002; 129: 133-9.
14. Matter M, Mumprecht S, Pinschewer D et al. Virus-induced polyclonal B cell activation improves protective CTL memory via retained CD27 expression on memory CTL. Eur J Immunol 2005; 35: 3229-39.
15. Belmonte L, Parodi C, Baré P, Malbrán A, Ruibal-Ares B, de Bracco MM. Factors involved in the generation of memory CD8+ T cells in patients with X- linked lymphoproliferative disease (XLP). Clin Exp Immunol 2007; 147: 456-64.
16. Irigoyen M, Primiani L, Felippo M et al. A flow cytometry evaluation of anti-FVIII antibodies: correlation with ELISA and Bethesda assay. Haemophilia 2011; 17: 267-74.
17. Verbruggen B, Novakova I, Wessels H, Boezeman J, van der Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
18. Appay V, van Lier R, Sallusto F, Roederer M. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry Part A 2008; 73A: 975-83.
19. Reipert B, Allacher P, Hausl C et al. Modulation of factor VIII-specific memory B cells. Haemophilia 2010; 16: 25-34.
20. Van Helden P, Van Haren S, Fijnvandraat K, van den Berg H, Voorberg J. Factor VIII-specific B cell responses in haemophilia A patients with inhibitors. Haemophilia 2010; 16: 35-43.
21. McHeyzer-Willams L, McHeyzer-Willams M. Antigen-specific memory B cell development. Annu Rev Immunol 2005; 23: 487-513.
22. Moser K, Tokoyoda K, Radbruch A, MacLennan I, Manz R. Stromal niches, plasma cell differentiation and survival. Curr Opin Immunol 2006; 18: 265-70.
23. Hayakawa K, Ishii R, Yamasaki K, Kishimoto T, Hardy R. Isolation of high-affinity memory B cells: phycoerythrin as a probe for antigen-binding cells. Proc Natl Acad Sci 1987; 84: 1379-83.
24. Klein U, Kuppers R, Rajewsky K. Evidence for a large compartment of IgM-expressing memory B cells in humans. Blood 1997; 89: 1288-98.
25. Tangye S, Good K. Human IgM+CD27+ B cells: memory B cells or 'memory' B cells? J Immunol 2007; 179: 13-9.